scholarly journals Is dose modification or discontinuation of nilotinib necessary in nilotinib-induced hyperbilirubinemia?

2021 ◽  
Vol 9 (6) ◽  
pp. 488-495
Author(s):  
You-Wen Tan
Keyword(s):  
Dose Modification

Development of age-dependent dose modification factors for acute radiation lethality

2019 ◽  
Vol 96 (1) ◽  
pp. 67-80 ◽  
Author(s):  
Daniela Stricklin ◽  
Robert Prins ◽  
Jacob Bellman
Keyword(s):  
Acute Radiation ◽  
Dose Modification ◽  
Age Dependent

scholarly journals Dose Modification

2020 ◽  
Author(s):  
Keyword(s):  
Dose Modification

Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate-to-severe plaque psoriasis

2018 ◽  
Vol 29 (8) ◽  
pp. 792-796 ◽  
Author(s):  
Rosa M. Romero-Jimenez ◽  
Vicente Escudero-Vilaplana ◽  
Ofelia Baniandres Rodriguez ◽  
Estela García Martín ◽  
Ana Mateos Mayo ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Clinical Factors ◽  
Severe Plaque Psoriasis ◽  
Dose Modification

Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic Chemotherapy

2015 ◽  
Vol 25 (7) ◽  
pp. 1331-1336 ◽  
Author(s):  
Caroline C. Billingsley ◽  
Samuel N. Jacobson ◽  
Sarah M. Crafton ◽  
Aleia K. Crim ◽  
Quan Li ◽  
...  
Keyword(s):  
Primary Outcome ◽  
Adjusted Relative Risk ◽  
Gynecologic Malignancies ◽  
Treatment Delays ◽  
Dose Modification ◽  
Regimen Change ◽  
Gynecology Oncology ◽  
Grade 3 ◽  
Dose Delay ◽  
Common Malignancy

ObjectiveWe assessed the safety and efficacy of administration of pegfilgrastim on the same day compared with standard administration 24 to 72 hours after chemotherapy in patients with gynecologic malignancies.MethodsA retrospective review was conducted on patients undergoing pegfilgrastim to mitigate the myelosuppressive consequences of chemotherapy. The primary outcome was incidence of grade 3 to 4 neutropenia following pegfilgrastim for same-day administration (D1) versus standard administration (D2+). Secondary outcomes included dose delay, regimen change, hospitalization due to neutropenia, and incidence of febrile neutropenia.ResultsFour hundred twenty-one patients with 2071 administrations of pegfilgrastim were included. Five hundred six administrations of pegfilgrastim were given on D1 compared with 1565 administrations on D2+. The most common malignancy was ovarian cancer (79.1%), followed by endometrial (14.5%). Comparing the D1 and D2+ cohorts, noninferiority was not established for the incidence of grade 3 to 4 neutropenia (2.6% vs 1.8%, adjusted relative risk [aRR], 1.6; 90% confidence interval [CI], 0.87–3.2) or dose modification (6.5% vs 4.9%; aRR, 1.3; 90% CI, 0.9–1.8). However, the rate of treatment delays (7.3% vs 9.4%; aRR, 0.8; 90% CI, 0.6–1.1) in the D1 and D2+ groups suggested that delays in the D1 group were not more common than in the D2+ group.ConclusionsThe incidence of hematologic toxicities and dose modification in patients receiving same-day pegfilgrastim were not as low as in those undergoing standard administration. However, treatment delays were found to be no more frequent in those receiving same-day pegfilgrastim versus standard administration. Same-day administration of pegfilgrastim is a reasonable option.

Prevention of postsurgical bleeding in oral surgery using tranexamic acid without dose modification of oral anticoagulants

1993 ◽  
Vol 51 (11) ◽  
pp. 1211-1216 ◽  
Author(s):  
G. Ramström ◽  
S. Sindet-Pedersen ◽  
G. Hall ◽  
M. Blombäck ◽  
U. Älander
Keyword(s):  
Tranexamic Acid ◽  
Oral Surgery ◽  
Oral Anticoagulants ◽  
Dose Modification

scholarly journals Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?

Drugs in R&D ◽  
2017 ◽  
Vol 17 (3) ◽  
pp. 461-467 ◽  
Author(s):  
Paolo Grassi ◽  
Elena Verzoni ◽  
Raffaele Ratta ◽  
Luca Porcu ◽  
Michele Prisciandaro ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
First Line ◽  
Dose Modification

scholarly journals Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Bhanu Vakkalanka ◽  
Brian K. Link
Keyword(s):  
Effective Treatment ◽  
Hodgkin Lymphoma ◽  
Significant Risk ◽  
Therapeutic Use ◽  
Colony Stimulating Factors ◽  
Definitive Evidence ◽  
Dose Modification ◽  
Chemotherapy Regime ◽  
Highly Effective ◽  
Abvd Chemotherapy

A combination of Adriamycin (a.k.a. Doxorubicin), Bleomycin, Vinblastine, and Dacarbazine (ABVD) is the most commonly used chemotherapy regime for Hodgkin lymphoma. This highly effective treatment is associated with a significant risk of neutropenia. Various strategies are adopted to counter this commonly encountered problem, including dose modification, use of colony stimulating factors, and prophylactic or therapeutic use of antibiotics. Data to support these approaches is somewhat controversial, and in keeping with the paucity of definitive evidence, there is a wide disparity in the management of neutropenia in patients receiving ABVD chemotherapy. This paper summarizes the evidence for managing ABVD-related neutropenia during the treatment of Hodgkin lymphoma.

Sign in / Sign up

Export Citation Format

Share Document